DreamCIS, Inc.
Financials
Valuation Metrics
DreamCIS, Inc.'s Market Cap is ₩978B. At end of 2025 it was ₩1570B. Ranked #1233 of 2,405 in KR market (top 51%), #665 of 1,627 on KOSDAQ (top 41%), #137 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 97.79B KRW | KR#1,233/2,405 Sec#137/231 |
| Revenue | 73.28B KRW | KR#1,593/2,405 Sec#103/231 |
| Net Income | 640.0M KRW | KR#1,511/2,405 Sec#104/231 |
| Total Assets | 159.49B KRW | KR#1,467/2,405 Sec#112/231 |
| Net Assets | 84.19B KRW | KR#1,548/2,405 Sec#123/231 |
| Employees | 358 | KR#676/2,405 Sec#59/231 |
| Value | ||
| P/E | 152.78x | KR#1,514/2,405 Sec#101/231 |
| P/B | 1.16x | KR#1,649/2,405 Sec#108/231 |
| P/S | 1.33x | KR#1,627/2,405 Sec#94/231 |
| EV/EBITDA | 17.49x | KR#978/2,405 Sec#57/231 |
| FCF Yield | 13.85% | KR#522/2,405 Sec#16/231 |
| Profitability | ||
| ROE | 0.76% | KR#1,497/2,405 Sec#105/231 |
| ROA | 0.40% | KR#1,495/2,405 Sec#105/231 |
| Op. Margin | 7.10% | KR#714/2,405 Sec#56/231 |
| Revenue Growth | 14.96% | KR#684/2,405 Sec#65/231 |
| Earnings Growth | -83.20% | KR#1,122/2,405 Sec#74/231 |
| Financial Health | ||
| Debt Ratio | 89.45% | KR#1,447/2,405 Sec#170/231 |
| Total Debt | 14.98B KRW | KR#1,491/2,405 Sec#128/231 |
| FCF | 13.54B KRW | KR#623/2,405 Sec#35/231 |
| Cash | 21.75B KRW | KR#1,201/2,405 Sec#84/231 |
| Current Ratio | 1.04x | KR#1,671/2,405 Sec#168/231 |
| Net Debt/EBITDA | -1.30x | KR#318/2,405 Sec#16/231 |
| Performance | ||
| 1Y Return | -7.13% | KR#814/2,405 Sec#44/231 |
| 1M Return | 8.16% | KR#125/2,405 Sec#12/231 |
| From 52W High | -53.99% | KR#1,351/2,405 Sec#108/231 |
| 1Y MDD | -68.14% | KR#1,873/2,405 Sec#158/231 |
| Trading | ||
| Volume | 88,129 shares | KR#687/2,405 Sec#74/231 |
| Trading Value | 347.5M KRW | KR#930/2,405 Sec#104/231 |
| Foreign Own. | 50.12% | KR#35/2,405 Sec#2/231 |
| Per Share | ||
| EPS | 26 KRW | KR#1,533/2,405 Sec#105/231 |
| BPS | 3,422 KRW | KR#1,778/2,405 Sec#132/231 |
Company Info
Dream CIS, a Clinical Research Organization (CRO) established in 2000, saw China's top CRO, Tigermed, acquire a stake in 2015. The company provides full-range services including clinical trial design, consulting, and monitoring, as well as comprehensive specialized services such as drug clinical trials, post-market surveillance, and statistical analysis. Leveraging Tigermed's global network, Dream CIS establishes a foundation for multinational clinical trial orders and secures competitiveness through the integration of standard operating procedures. Dream CIS was established in 2000 and is headquartered in Jongno-gu, Seoul.